John M Kovarik

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. doi request reprint Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients
    John M Kovarik
    Clinical Pharmacology and Clinical Research, Novartis Pharmaceuticals, Basel, Switzerland
    Transplantation 91:317-22. 2011
  2. ncbi request reprint Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    J Heart Lung Transplant 25:440-6. 2006
  3. doi request reprint Cyclosporine pharmacokinetics and blood pressure responses after conversion to once-daily dosing in maintenance liver transplant patients
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Clin Transplant 22:68-75. 2008
  4. doi request reprint The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects
    John M Kovarik
    Novartis Pharma, Building WSJ 210 423, 4002, Basel, Switzerland
    Eur J Clin Pharmacol 64:457-63. 2008
  5. ncbi request reprint Ethnic sensitivity study of fingolimod in white and Asian subjects
    J M Kovarik
    Novartis Pharmaceuticals, Basle, Switzerland
    Int J Clin Pharmacol Ther 45:98-109. 2007
  6. ncbi request reprint Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Biopharm Drug Dispos 28:97-104. 2007
  7. ncbi request reprint Exposure-efficacy relationships of a fingolimod-everolimus regimen in kidney transplant patients at risk for delayed graft function
    J M Kovarik
    Department of Clinical Pharmacology, Novartis Pharma, Basel, Switzerland
    Transplant Proc 38:3479-82. 2006
  8. ncbi request reprint Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus
    J M Kovarik
    Novartis Pharma, Basel, Switzerland
    Transplant Proc 38:3456-8. 2006
  9. ncbi request reprint Everolimus drug interactions: application of a classification system for clinical decision making
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland and East Hanover, NJ, USA
    Biopharm Drug Dispos 27:421-6. 2006
  10. doi request reprint A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod
    John M Kovarik
    Novartis Pharma, 4002 Basel, Switzerland
    J Clin Pharmacol 48:303-10. 2008

Detail Information

Publications60

  1. doi request reprint Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients
    John M Kovarik
    Clinical Pharmacology and Clinical Research, Novartis Pharmaceuticals, Basel, Switzerland
    Transplantation 91:317-22. 2011
    ..Sotrastaurin is a protein kinase C inhibitor in the development for prevention of organ rejection after renal transplantation...
  2. ncbi request reprint Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    J Heart Lung Transplant 25:440-6. 2006
    ..In this study we evaluated exposure, safety and efficacy data from an international trial of everolimus. We sought to identify a tolerated and efficacious range for blood levels of this agent in maintenance lung transplant recipients...
  3. doi request reprint Cyclosporine pharmacokinetics and blood pressure responses after conversion to once-daily dosing in maintenance liver transplant patients
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Clin Transplant 22:68-75. 2008
    ..Conversion to once-daily dosing was associated with a decrease in nighttime mean arterial blood pressure...
  4. doi request reprint The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects
    John M Kovarik
    Novartis Pharma, Building WSJ 210 423, 4002, Basel, Switzerland
    Eur J Clin Pharmacol 64:457-63. 2008
    ..The authors determined the effect of combining a single dose of fingolimod with steady-state atenolol or diltiazem on heart rate and mean arterial pressure...
  5. ncbi request reprint Ethnic sensitivity study of fingolimod in white and Asian subjects
    J M Kovarik
    Novartis Pharmaceuticals, Basle, Switzerland
    Int J Clin Pharmacol Ther 45:98-109. 2007
    ..The authors compared the pharmacokinetics and pharmacological effects of the immunomodulator fingolimod in healthy white and Asian subjects for potential ethnic differences...
  6. ncbi request reprint Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Biopharm Drug Dispos 28:97-104. 2007
    ..The pharmacokinetics and lymphocyte responses to the immunomodulator fingolimod (FTY720) were characterized after oral and intravenous administration...
  7. ncbi request reprint Exposure-efficacy relationships of a fingolimod-everolimus regimen in kidney transplant patients at risk for delayed graft function
    J M Kovarik
    Department of Clinical Pharmacology, Novartis Pharma, Basel, Switzerland
    Transplant Proc 38:3479-82. 2006
    ..We explored relationships between blood levels of fingolimod (FTY720) and everolimus versus treated biopsy-proven acute rejection (BPAR) in an open-label trial in de novo kidney transplant recipients...
  8. ncbi request reprint Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus
    J M Kovarik
    Novartis Pharma, Basel, Switzerland
    Transplant Proc 38:3456-8. 2006
    ..We characterized the pharmacokinetics of tacrolimus and everolimus in a combined immunosuppressive regimen...
  9. ncbi request reprint Everolimus drug interactions: application of a classification system for clinical decision making
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland and East Hanover, NJ, USA
    Biopharm Drug Dispos 27:421-6. 2006
    ..This rational and systematic approach to drug interactions on everolimus yielded clinically useful, structured guidelines for dose adjustment...
  10. doi request reprint A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod
    John M Kovarik
    Novartis Pharma, 4002 Basel, Switzerland
    J Clin Pharmacol 48:303-10. 2008
    ..Isoproterenol did not alter the pharmacokinetics of fingolimod. The pure beta-agonist isoproterenol can reverse the heart rate reduction that occurs transiently after initiating fingolimod treatment...
  11. ncbi request reprint Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus
    John M Kovarik
    Novartis Pharmaceuticals, Building WSJ 103 426, 4002 Basel, Switzerland
    Eur J Clin Pharmacol 62:361-6. 2006
    ..3-fold due to a pharmacokinetic interaction. We assessed this drug interaction for potential differences when the innovator formulation is replaced by a generic cyclosporine...
  12. doi request reprint Sotrastaurin single-dose pharmacokinetics in de novo liver transplant recipients
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland and East Hanover, NJ, USA
    Transpl Int 24:276-83. 2011
    ..Whether a higher dose of sotrastaurin is needed to compensate for this in the short-term after surgery will be addressed in future clinical trials...
  13. doi request reprint Overview of sotrastaurin clinical pharmacokinetics
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Ther Drug Monit 32:540-3. 2010
    ....
  14. doi request reprint Sotrastaurin and cyclosporine drug interaction study in healthy subjects
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Biopharm Drug Dispos 31:331-9. 2010
    ..The authors determined the effect of combining sotrastaurin with the calcineurin inhibitor cyclosporine on the pharmacokinetics and biomarker responses to both drugs...
  15. doi request reprint Sotrastaurin and tacrolimus coadministration: effects on pharmacokinetics and biomarker responses
    John M Kovarik
    Novartis Pharma, Building WSJ 210 427, 4002 Basel, Switzerland
    J Clin Pharmacol 50:1260-6. 2010
    ....
  16. ncbi request reprint Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration
    J M Kovarik
    Novartis Pharmaceuticals, 4002 Basel, Switzerland
    Int J Clin Pharmacol Ther 48:103-8. 2010
    ..The authors determined whether a pharmacokinetic interaction occurs between sotrastaurin and everolimus, both of which are substrates and inhibitors of CYP3A4...
  17. pmc The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Br J Clin Pharmacol 68:381-5. 2009
    ..Sotrastaurin is an immunosuppressant that reduces T-lymphocyte activation via protein kinase C inhibition. The effect of CYP3A4 inhibition by ketoconazole on the pharmacokinetics of sotrastaurin, a CYP3A4 substrate, was investigated...
  18. pmc The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects
    John M Kovarik
    Novartis Pharmaceuticals, Exploratory Development, Basel, Switzerland
    Br J Clin Pharmacol 66:199-206. 2008
    ..The authors determined whether intravenous atropine can prevent or counteract the negative chronotropic effect of the immunomodulator fingolimod...
  19. doi request reprint Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition
    John M Kovarik
    Novartis Pharma, Building WSJ 210 427, 4002 Basel, Switzerland
    J Clin Pharmacol 49:212-8. 2009
    ..The clinician, however, should be aware of this interaction and bear in mind the possibility of a fingolimod dose reduction based on clinical monitoring...
  20. ncbi request reprint FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction
    John M Kovarik
    Novartis Pharma, Basel, Switzerland
    Ann Pharmacother 38:1153-8. 2004
    ..FTY720 is a sphingosine-1-phosphate receptor agonist intended for use in immunoprophylaxis regimens to prevent acute rejection after organ transplantation...
  21. ncbi request reprint Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects
    John M Kovarik
    Novartis Pharma AG, Building WSJ 27 4093, 4002 Basel, Switzerland
    J Clin Pharmacol 44:532-7. 2004
    ..25 and 5 mg/day, respectively. Exposure-response modeling provided evidence that 5 mg/day FTY720 resulted in a near-maximal dynamic effect of this drug on lymphocytes...
  22. pmc Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Br J Clin Pharmacol 57:586-91. 2004
    ..This study was performed to provide guidance on administration with respect to meals and to measure pharmacologic responses in healthy subjects...
  23. ncbi request reprint Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Pharmacotherapy 22:154-9. 2002
    ....
  24. ncbi request reprint Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure
    John M Kovarik
    Novartis Pharmaceuticals, Novartis Pharma AG, Building WSJ 27 4093, 4002 Basel, Switzerland
    J Heart Lung Transplant 22:1117-25. 2003
    ..Everolimus-related adverse events were manageable up to the highest troughs (22 ng/ml) observed in this population. We could not derive a precise upper therapeutic concentration limit from these data...
  25. ncbi request reprint Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    J Clin Pharmacol 43:141-7. 2003
    ..The dispersible tablet formulation should be taken consistently either with or without food to minimize fluctuations in exposure over time...
  26. ncbi request reprint Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland 4002
    Am J Transplant 3:606-13. 2003
    ..Weight-adjusted dosing (mg/kg) does not appear warranted. Black patients may have lower bioavailability and/or higher clearance of everolimus compared with white patients...
  27. ncbi request reprint Effect of rifampin on apparent clearance of everolimus
    John M Kovarik
    Clinical Pharmacology Department, Novartis Pharmaceuticals, Basel, Switzerland
    Ann Pharmacother 36:981-5. 2002
    ..To assess the influence of the CYP3A4 enzyme inducer rifampin on the pharmacokinetics of the immunosuppressant everolimus to provide guidance for their coadministration...
  28. ncbi request reprint Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland and Rueil Malmaison, France
    Ther Drug Monit 26:499-505. 2004
    ..Maintaining everolimus troughs in the range 3 to 8 ng/mL in the first posttransplant year with reduced-exposure cyclosporine is associated with good efficacy and safety profiles...
  29. ncbi request reprint Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function
    John M Kovarik
    Novartis Pharma AG, Building WSJ 103 426, 4002 Basel, Switzerland
    J Clin Pharmacol 46:149-56. 2006
    ..For patients with severe hepatic impairment (Child-Pugh class C), a standard first dose of fingolimod could be given followed by a maintenance dose that is reduced by half from the normal maintenance dose...
  30. ncbi request reprint FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects
    Robert Schmouder
    Exploratory Development, Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA
    J Clin Pharmacol 46:895-904. 2006
    ..FTY720 did not increase the QRS or QT interval. These results confirm that the first dose of FTY720 has a mild to moderate negative chronotropic effect...
  31. ncbi request reprint Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Drugs Today (Barc) 40:101-9. 2004
    ..In clinical development trials, everolimus has demonstrated the ability to reduce the incidence of acute rejection episodes, cytomegalovirus infection and cardiac vasculopathy, thus addressing the primary causes of allograft dysfunction...
  32. ncbi request reprint Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    J Clin Pharmacol 42:222-8. 2002
    ....
  33. ncbi request reprint Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Transplantation 73:920-5. 2002
    ..Exposure, safety, and efficacy data from the two everolimus randomized, double-blind phase 3 trials were evaluated to identify a therapeutic concentration range applicable in de novo kidney transplantation...
  34. ncbi request reprint A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Transplantation 74:966-71. 2002
    ..The pharmacokinetics and immunodynamics of basiliximab were assessed in 39 pediatric de novo kidney allograft recipients to rationally chose a dose regimen for this age group...
  35. ncbi request reprint Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Am J Transplant 3:1576-80. 2003
    ..Dosing of everolimus needs to be adjusted to take into account an average threefold increase in everolimus exposure when cyclosporine is added to the regimen...
  36. ncbi request reprint Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    J Clin Pharmacol 42:95-9. 2002
    ..Therapeutic monitoring of everolimus concentrations would be helpful after the removal of cyclosporine to individually titrate everolimus exposure...
  37. ncbi request reprint Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications
    J M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Clin Pharmacol Ther 70:247-54. 2001
    ..Concomitant administration of potent inhibitors of the cytochrome P450 isozyme CYP3A may reduce everolimus clearance and increase its blood concentrations...
  38. ncbi request reprint A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation
    J M Kovarik
    Novartis Pharmaceuticals, Medizinische Hochschule, , Switzerland
    Clin Pharmacol Ther 69:201-9. 2001
    ....
  39. ncbi request reprint Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine
    J M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Clin Pharmacol Ther 69:48-56. 2001
    ..CONCLUSIONS: Everolimus exhibited dose-proportional, stable exposure during the first post-transplant year. For a 4-fold range of everolimus doses there were no differential effects on cyclosporine dosing or pharmacokinetics...
  40. doi request reprint Clinical pharmacokinetics of fingolimod
    Olivier J David
    Novartis Institutes for BioMedical Research, Basel, Switzerland
    Clin Pharmacokinet 51:15-28. 2012
    ..Fingolimod is thus a promising new therapy for eligible patients with MS, with a predictable pharmacokinetic profile that allows effective once-daily oral dosing...
  41. ncbi request reprint Administration diluents differentiate Neoral from a generic cyclosporine oral solution
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Clin Transplant 16:306-9. 2002
    ..Cyclosporine bioavailability is unaltered when Neoral is administered diluted in apple juice or orange juice compared with tap water which conforms to the cyclosporine product label...
  42. ncbi request reprint Overview of FTY720 clinical pharmacokinetics and pharmacology
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Ther Drug Monit 26:585-7. 2004
    ..An association among FTY720 blood concentration, decrease in lymphocyte counts, and freedom from acute rejection episodes has been observed in early clinical development trials in de novo kidney transplantation...
  43. ncbi request reprint Effect of multiple-dose erythromycin on everolimus pharmacokinetics
    J M Kovarik
    Novartis Pharma, Building WSJ 27 P081, 4002 Basel, Switzerland
    Eur J Clin Pharmacol 61:35-8. 2005
    ..We sought to quantify the influence of the CYP3A inhibitor erythromycin on the pharmacokinetics of everolimus, a CYP3A substrate...
  44. ncbi request reprint Blood concentrations of everolimus are markedly increased by ketoconazole
    J M Kovarik
    Novartis Pharma, Building WSJ 27 P081, 4002 Basel, Switzerland
    J Clin Pharmacol 45:514-8. 2005
    ..Everolimus did not appear to alter ketoconazole predose concentrations. Given the magnitude of this drug interaction, use of ketoconazole should be avoided if possible in everolimus-treated patients...
  45. pmc Pharmacokinetic interaction between verapamil and everolimus in healthy subjects
    J M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Br J Clin Pharmacol 60:434-7. 2005
    ..We sought to define the influence of verapamil, an inhibitor of CYP3A and P-glycoprotein, on the pharmacokinetics of everolimus, a substrate of this enzyme and transporter...
  46. ncbi request reprint Screening for basiliximab exposure-response relationships in renal allotransplantation
    J M Kovarik
    Novartis Pharma AG, Basel, Switzerland
    Clin Transplant 13:32-8. 1999
    ..Further exploration for exposure-effect relationships in a larger population is warranted...
  47. ncbi request reprint Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients
    J M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Clin Transplant 15:123-30. 2001
    ..Hence, no dosing adjustment is deemed necessary when basiliximab is used in triple immunosuppressive therapy including either azathioprine or mycophenolate mofetil...
  48. ncbi request reprint Cyclosporine absorption profiles in pediatric kidney and liver transplant patients
    J M Kovarik
    Novartis Pharma AG, Building WSJ 27 4093, 4002 Basel, Switzerland
    Pediatr Nephrol 18:1275-9. 2003
    ..liver), and across age groups (pediatric vs. adult patients). Average C2 values achieved with current pediatric cyclosporine dosing practices cluster around the target C2 ranges recommended for adults...
  49. ncbi request reprint Cyclosporin pharmacokinetics in the elderly
    J M Kovarik
    Department of Clinical Pharmacology, Novartis Pharma AG, Basel, Switzerland
    Drugs Aging 15:197-205. 1999
    ..Based on the available cyclosporin pharmacokinetic data in adults, no age-related administration adaptations appear necessary for its use in the elderly...
  50. ncbi request reprint New insights on SOM230, a universal somatostatin receptor ligand
    V Boerlin
    Novartis Pharma AG, Basel, Switzerland
    J Endocrinol Invest 26:14-6. 2003
  51. doi request reprint Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data
    Chiaki Tanaka
    Novartis Pharmaceuticals Corp, East Hanover, NJ, USA
    J Clin Oncol 26:1596-602. 2008
    ....
  52. ncbi request reprint Basiliximab in pediatric liver transplantation: a pharmacokinetic-derived dosing algorithm
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Pediatr Transplant 6:224-30. 2002
    ..The first dose should be given within 6 h after organ perfusion and the second on day 4 after transplantation. A supplemental dose may be considered for patients with a large volume of drained ascites fluid relative to body size...
  53. ncbi request reprint Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases
    John M Kovarik
    Novartis Pharmaceuticals, 4002 Basel, Switzerland
    Expert Opin Emerg Drugs 8:47-62. 2003
    ....
  54. ncbi request reprint Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment
    J M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Clin Pharmacol Ther 70:425-30. 2001
    ..Therapeutic monitoring would be a helpful adjunct to subsequent titration of everolimus exposure in this subpopulation. Everolimus has not been assessed in patients with severe hepatic impairment...
  55. ncbi request reprint FTY720 pharmacokinetics in mild to moderate hepatic impairment
    J M Kovarik
    Novartis Pharma, Building WSJ 27 P081, 4002 Basel, Switzerland
    J Clin Pharmacol 45:446-52. 2005
    ..Although hepatic impairment elicited changes in the disposition of FTY720, the magnitude of these changes suggests that the FTY720 dose does not need to be adjusted in mild or moderate hepatic-impaired patients...
  56. ncbi request reprint Therapeutic drug monitoring for everolimus in heart transplant recipients: flawed model or a model for future use?
    Randall C Starling
    Am J Transplant 5:2330. 2005
  57. ncbi request reprint Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling
    Randall C Starling
    Department of Cardiovascular Medicine, Kaufman Center for Heart Failure, Cleveland, OH, USA
    Am J Transplant 4:2126-31. 2004
    ..5 mg/day, showed that the simulated BPAR rate (with TDM) was 21% versus 26% in the group with fixed dosing. Therefore, TDM in heart transplantation could optimize immunosuppressive efficacy and reduce treatment-related toxicity...
  58. ncbi request reprint Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions
    Christiane Knoop
    Department of Chest Medicine, Erasme University Hospital, Brussels, Belgium
    Transplantation 76:683-8. 2003
    ....
  59. ncbi request reprint Everolimus in pediatric de nova renal transplant patients
    Peter F Hoyer
    Department of Pediatric Nephrology, Universitätsklinik Essen, Hufelandstr 55, D 45122 Essen, Germany
    Transplantation 75:2082-5. 2003
    ..The steady-state pharmacokinetics of everolimus were longitudinally assessed in pediatric de novo kidney allograft recipients during a 6-month period...
  60. doi request reprint Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
    ANNE O'DONNELL
    Royal Marsden Hospital, Sutton, Surrey, UK
    J Clin Oncol 26:1588-95. 2008
    ..To identify the optimal regimen and dosage of the oral mammalian target of rapamycin inhibitor everolimus (RAD001)...